Orfiril Magasýruþolin tafla 150 mg Ισλανδία - Ισλανδικά - LYFJASTOFNUN (Icelandic Medicines Agency)

orfiril magasýruþolin tafla 150 mg

desitin arzneimittel gmbh - natrii valproas - magasýruþolin tafla - 150 mg

Orfiril Magasýruþolin tafla 600 mg Ισλανδία - Ισλανδικά - LYFJASTOFNUN (Icelandic Medicines Agency)

orfiril magasýruþolin tafla 600 mg

desitin arzneimittel gmbh - natrii valproas - magasýruþolin tafla - 600 mg

Orfiril Mixtúra, lausn 60 mg/ml Ισλανδία - Ισλανδικά - LYFJASTOFNUN (Icelandic Medicines Agency)

orfiril mixtúra, lausn 60 mg/ml

desitin arzneimittel gmbh - natrii valproas - mixtúra, lausn - 60 mg/ml

Orfiril Retard Forðatafla 300 mg Ισλανδία - Ισλανδικά - LYFJASTOFNUN (Icelandic Medicines Agency)

orfiril retard forðatafla 300 mg

desitin arzneimittel gmbh - natrii valproas - forðatafla - 300 mg

Duzallo Ευρωπαϊκή Ένωση - Ισλανδικά - EMA (European Medicines Agency)

duzallo

grunenthal gmbh - allópúrinól, lesinurad - gigt - antigout undirbúningur - duzallo er ætlað í fullorðnir fyrir meðferð hyperuricaemia í þvagsýrugigt sjúklingar sem hafa ekki náð miða blóðvatn lægri sýru stigum með fullnægjandi skammt af allópúrinól einn.

Zurampic Ευρωπαϊκή Ένωση - Ισλανδικά - EMA (European Medicines Agency)

zurampic

grünenthal gmbh - lesinurad - blóðsykurshækkun - antigout undirbúningur - zurampic, ásamt xantín oxidasa hemil, er ætlað í fullorðnir fyrir venjulega meðferð hyperuricaemia í þvagsýrugigt sjúklingar (með eða án tophi) sem hafa ekki náð miða blóðvatn lægri sýru stigum með fullnægjandi skammt af xantín oxidasa hemil einn.

Adalat Oros Forðatafla 30 mg Ισλανδία - Ισλανδικά - LYFJASTOFNUN (Icelandic Medicines Agency)

adalat oros forðatafla 30 mg

bayer ab* - nifedipinum inn - forðatafla - 30 mg

Vimpat Ευρωπαϊκή Ένωση - Ισλανδικά - EMA (European Medicines Agency)

vimpat

ucb pharma sa - lacosamíð - flogaveiki - antiepileptics, - vimpat er ætlað sem einlyfjameðferð og viðbótarmeðferð við meðhöndlun á flogaveiki með eða án aukakvilla hjá fullorðnum, unglingum og börnum frá 4 ára með flogaveiki.

Xtandi Ευρωπαϊκή Ένωση - Ισλανδικά - EMA (European Medicines Agency)

xtandi

astellas pharma europe b.v. - enzalutamíð - blöðruhálskirtli - innkirtla meðferð - xtandi is indicated for:the treatment of adult men with metastatic hormone-sensitive prostate cancer (mhspc) in combination with androgen deprivation therapy (see section 5. the treatment of adult men with high-risk non-metastatic castration-resistant prostate cancer (crpc) (see section 5. the treatment of adult men with metastatic crpc who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated (see section 5. the treatment of adult men with metastatic crpc whose disease has progressed on or after docetaxel therapy.

Lacosamide Accord Ευρωπαϊκή Ένωση - Ισλανδικά - EMA (European Medicines Agency)

lacosamide accord

accord healthcare s.l.u. - lacosamíð - flogaveiki - antiepileptics, - lacosamide accord is indicated as monotherapy in the treatment of partial-onset seizures with or without secondary generalisation in adults, adolescents and children from 4 years of age with epilepsy. lacosamide accord is indicated as adjunctive therapy•         in the treatment of partial-onset seizures with or without secondary generalisation in adults, adolescents and children from 4 years of age with epilepsy. •         in the treatment of primary generalised tonic-clonic seizures in adults, adolescents and children from 4 years of age with idiopathic generalised epilepsy.